BioSpace News Archive

Filterlex Medical, a cardiovascular medical device startup, announced that it has been selected to receive €7 Million equity investment from the European Innovation Council Accelerator.

Renovia Inc. (“Renovia”), today announced that Neurourology and Urodynamics, the official journal of the Society for Urodynamics & Female Urology and the International Continence Society, published a pilot study supporting that use of the leva® Pelvic Health System may be effective in treating symptoms of fecal incontinence (FI) in women.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company’s Board of Directors, effective January 1, 2022.

A new study found that changes in specific genes may contribute each year to the roughly 400 sudden unexplained deaths in children aged one year and older – and separately from sudden infant death syndrome.

CytRx Corporation today highlighted ImmunityBio, Inc.'s (NASDAQ: IBRX) (“ImmunityBio”) recent clinical developments in the study of aldoxorubicin to treat various cancers.

GeneCentric Therapeutics announced today the completion of its Piedmont Study, conducted in collaboration with Atrium Health Levine Cancer Institute.

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies and delivery solutions for liquid and solid tumors, today announced the completion of a $41 million Series B2 financing.

Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids in people with moderate-to-severe atopic dermatitis in Eli Lilly and Company’s third pivotal Phase 3 trial.

MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces the expansion of its Board, with the appointment of Susan Clement-Davies and Professor Sir Robert Lechler as Independent Directors, effective 1 January 2022.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the appointment of Karen Richards as its Vice President of Regulatory Affairs.